typo fix & new paper

content/clusters/20A.S.154K.478K.md

@@ -1,7 +1,7 @@
 The Pango lineage `B.1.617` includes both <Var name={'20A/S:154K'}/> and its sister lineage <Var name={'20A/S:478K'}/>. 
 `B.1.617` was first detected in late 2020 in India, and has appeared to expand rapidly.
 
-These sequences have Spike mutations at positions <AaMut mut={'S:L452D'}/> (see <Var name={'20C/S:452R'}/> page for more details) and <Mut name="S:P681"/>, both of which impact antibody binding.
+These sequences have Spike mutations at positions <AaMut mut={'S:L452R'}/> (see <Var name={'20C/S:452R'}/> page for more details) and <Mut name="S:P681"/>, both of which impact antibody binding.
 
 In addition, many sequences have mutation <AaMut mut={'S:G142D'}/>, in the N-terminal domain, which is an escape mutatant to some antibodies ([McCallum et al., bioRxiv](https://www.biorxiv.org/content/10.1101/2021.01.14.426475v1)) and has appeared in viruses grown in the presence of a monoclonal antibody ([Suryadevara et al, Cell](https://www.cell.com/cell/fulltext/S0092-8674(21)00357-3)).
 

content/clusters/20C.S.484K.md

@@ -14,6 +14,7 @@ Two sister-clades to this variant carry many of the same mutations but lack <Mut
 
 These can be see on the dedicated build (link at top of this page) by zooming in near to <Var name="20A/S:484K" prefix=""/> and coloring by Spike position 477.
 
+- <Var name="20C/S:484K"/> was not linked with more severe disease or an increased risk of vaccine-breakthrough infection (<LinkExternal href="https://www.cdc.gov/mmwr/volumes/70/wr/mm7019e1.htm">Thompson et al., MMWR</LinkExternal>)
 - <AaMut mut={"S:A701V"}/> is near the furin cleavage site, and <AaMut mut={"S:D253G"}/> is located in a region of the N-terminal domain which is a target for neutralizing antibodies (<LinkExternal href="https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v2">Annavajhala et al., medRxiv</LinkExternal>)
 - The variant was observed to rise rapidly in prevalence in New York (<LinkExternal href="https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v2">Annavajhala et al., medRxiv</LinkExternal>, <LinkExternal href="https://www.medrxiv.org/content/10.1101/2021.02.26.21251868v1">Lasek-Nesselquist et al., medRxiv</LinkExternal>)
 - Neutralization by convalescent plasma or vaccine sera was reduced by 4.1-fold or 3.3-3.6 fold, respectively, compared to wild-type (<LinkExternal href="https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v2">Annavajhala et al., medRxiv</LinkExternal>)